LISINOPRIL by Teva is angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension in adult patients, older to lower blood pressure, mortality in treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction and 1 more indications. First approved in 2002.
Drug data last refreshed 22h ago
angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of…
Worked on LISINOPRIL at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)
A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects
Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition
Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant
A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril